This Cannabis Stock Got Destroyed in 2025. Can Trump Make 2026 a Different Story?

Group 1 - Cannabis stocks are gaining attention from investors, with significant increases observed in various companies over the past week [1] - The year-to-date (YTD) returns of cannabis companies show a diverse performance, with approximately half trading down and the other half experiencing substantial gains [2] - Incannex Healthcare (IXHL) has notably increased by 22% in the past month and 86% over the last six months, driven by President Trump's executive order to reclassify marijuana as a less dangerous drug [3] Group 2 - Incannex operates as a clinical-stage biopharma company focused on advancing medicinal cannabis and psychedelic therapies, with ongoing research in Australia for conditions like rheumatoid arthritis and sleep apnea [4] - The potential opening of the U.S. market for medical cannabis research could significantly enhance the sector, providing opportunities for companies like Incannex to conduct more research domestically [5] - The fundamentals of Incannex reflect its early-stage status, making it challenging to assess based on traditional financial metrics, as the company primarily raises capital for research and development [7]